PMID- 28234961 OWN - NLM STAT- MEDLINE DCOM- 20170821 LR - 20231112 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 2 DP - 2017 TI - Interleukin-10 reorganizes the cytoskeleton of mature dendritic cells leading to their impaired biophysical properties and motilities. PG - e0172523 LID - 10.1371/journal.pone.0172523 [doi] LID - e0172523 AB - Interlukin-10 (IL-10) is an immunomodulatory cytokine which predominantly induces immune-tolerance. It has been also identified as a major cytokine in the tumor microenvironment that markedly mediates tumor immune escape. Previous studies on the roles of IL-10 in tumor immunosuppression mainly focus on its biochemical effects. But the effects of IL-10 on the biophysical characteristics of immune cells are ill-defined. Dendritic cells (DCs) are the most potent antigen-presenting cells and play a key role in the anti-tumor immune response. IL-10 can affect the immune regulatory functions of DCs in various ways. In this study, we aim to explore the effects of IL-10 on the biophysical functions of mature DCs (mDCs). mDCs were treated with different concentrations of IL-10 and their biophysical characteristics were identified. The results showed that the biophysical properties of mDCs, including electrophoresis mobility, osmotic fragility and deformability, as well as their motilities, were impaired by IL-10. Meanwhile, the cytoskeleton (F-actin) of mDCs was reorganized by IL-10. IL-10 caused the alternations in the expressions of fasin1 and profilin1 as well as the phosphorylation of cofilin1 in a concentration-dependent fashion. Moreover, Fourier transformed infrared resonance data showed that IL-10 made the status of gene transcription and metabolic turnover of mDCs more active. These results demonstrate a new aspect of IL-10's actions on the immune system and represent one of the mechanisms for immune escape of tumors. It may provide a valuable clue to optimize and improve the efficiency of DC-based immunotherapy against cancer. FAU - Xu, Xiaoli AU - Xu X AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Hemorheology Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R.China. FAU - Liu, Xianmei AU - Liu X AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Hemorheology Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R.China. FAU - Long, Jinhua AU - Long J AD - Department of Head and Neck, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, P.R.China. FAU - Hu, Zuquan AU - Hu Z AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. FAU - Zheng, Qinni AU - Zheng Q AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. FAU - Zhang, Chunlin AU - Zhang C AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. FAU - Li, Long AU - Li L AD - Department of Nephropathy & Rheumatism, Third Affiliated Hospital, Guizhou Medical University, Duyun, P.R.China. FAU - Wang, Yun AU - Wang Y AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. FAU - Jia, Yi AU - Jia Y AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. FAU - Qiu, Wei AU - Qiu W AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. FAU - Zhou, Jing AU - Zhou J AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. FAU - Yao, Weijuan AU - Yao W AD - Hemorheology Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R.China. FAU - Zeng, Zhu AU - Zeng Z AD - Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, P.R. China. AD - Engineering Center of Medical Biotechnology Application, Guizhou Medical University, Guiyang, P.R. China. AD - School of Biology and Engineering, Guizhou Medical University, Guiyang, P.R. China. LA - eng PT - Journal Article DEP - 20170224 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Actins) RN - 0 (Cofilin 1) RN - 0 (FAS protein, human) RN - 0 (IL10 protein, human) RN - 0 (PFN1 protein, human) RN - 0 (Profilins) RN - 0 (Recombinant Proteins) RN - 0 (fas Receptor) RN - 130068-27-8 (Interleukin-10) SB - IM MH - Actins/genetics/immunology MH - Cell Movement/*drug effects MH - Cofilin 1/genetics/immunology MH - Cytoskeleton/chemistry/*drug effects MH - Dendritic Cells/cytology/*drug effects/immunology MH - Dose-Response Relationship, Immunologic MH - Gene Expression Regulation MH - Humans MH - Interleukin-10/*pharmacology MH - Microtubules/chemistry/*drug effects MH - Phosphorylation/drug effects MH - Primary Cell Culture MH - Profilins/genetics/immunology MH - Recombinant Proteins/pharmacology MH - Signal Transduction MH - Transcription, Genetic MH - fas Receptor/genetics/immunology PMC - PMC5325303 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2017/02/25 06:00 MHDA- 2017/08/22 06:00 PMCR- 2017/02/24 CRDT- 2017/02/25 06:00 PHST- 2016/09/29 00:00 [received] PHST- 2017/02/06 00:00 [accepted] PHST- 2017/02/25 06:00 [entrez] PHST- 2017/02/25 06:00 [pubmed] PHST- 2017/08/22 06:00 [medline] PHST- 2017/02/24 00:00 [pmc-release] AID - PONE-D-16-39083 [pii] AID - 10.1371/journal.pone.0172523 [doi] PST - epublish SO - PLoS One. 2017 Feb 24;12(2):e0172523. doi: 10.1371/journal.pone.0172523. eCollection 2017.